Drug Search Results
More Filters [+]

EGEN-001

Alternative Names: EGEN-001, egen-001-301, egen001301, egen 001 301, EGEN001, EGEN-001 (phIL-12-005/PPC), phIL-12-005
Latest Update: 2019-03-12
Latest Update Note: Clinical Trial Update

Product Description

An IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24708919/)

Mechanisms of Action: IL12 Analogue

Novel Mechanism: Yes

Modality: Gene Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: EGEN
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EGEN-001

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Peritoneal Cancer|Colorectal Cancer

Phase 1: Ovarian Cancer|Peritoneal Cancer|Clear Cell Adenocarcinoma|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Serous Cystadenocarcinoma|Endometrioid Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GOG-9928

P1

Completed

Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Serous Cystadenocarcinoma|Endometrioid Carcinoma|Ovarian Cancer|Clear Cell Adenocarcinoma|Peritoneal Cancer

2014-12-30

EGEN-001-301

P2

Terminated

Colorectal Cancer|Peritoneal Cancer

2014-07-01

EGEN-001-201

P1

Completed

Peritoneal Cancer|Ovarian Cancer

2009-11-01

EGEN-001-101

P1

Terminated

Peritoneal Cancer|Ovarian Cancer

2006-10-01

Recent News Events

Date

Type

Title